TransCode Therapeutics, Inc.

TransCode Therapeutics is a Boston-based biotechnology company focused on developing innovative treatments for metastatic cancer. The company's primary focus is on targeting microRNA-10b, a key regulator of metastatic cell viability, using its proprietary TTX delivery platform. This platform utilizes iron oxide nanoparticles designed to efficiently deliver therapeutic payloads, such as oligonucleotides, to tumors and metastases while sparing healthy tissue. TransCode has demonstrated promising pre-clinical results in models of metastatic breast cancer and pancreatic cancer, with TTX-MC138 leading to significant regression of disease without recurrence.

TransCode's mission is to deliver a cancer-free future for all patients by overcoming the challenges of targeted drug delivery. In addition to their lead candidate, TTX-MC138, they are developing a pipeline of other therapeutic candidates with different mechanisms of action, including immunotherapy, gene editing, and radiotherapy. They are also exploring the potential for diagnostic applications of their TTX platform, which could lead to earlier detection and monitoring of cancer. With their world-class team and innovative approach, TransCode is poised to make a significant impact in the fight against cancer.

TransCode Therapeutics prioritizes its employees, fostering an inclusive and diverse work environment where individuals thrive and give back to their communities. While the specific benefits offered are not explicitly detailed on the company website, the emphasis on employee well-being suggests a comprehensive package potentially including health insurance, retirement plans, paid time off, professional development opportunities, and other benefits common to the biotechnology industry.

TransCode Therapeutics is a Boston-based biotechnology company focused on delivering a cancer-free future by developing targeted therapies to treat metastatic cancer. The company believes that cancer can be overcome through the intelligent design and efficient delivery of therapeutics. Their lead therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability. TransCode's proprietary delivery platform, TTX, overcomes the challenges of delivering therapeutic payloads to tumors and metastases, opening the door to a broad array of cancer therapies and improving treatment outcomes for patients.

TransCode Therapeutics cultivates a culture focused on innovation, collaboration, and inclusivity. They value their employees as their most important asset, fostering an environment where individuals can thrive, contribute to a shared vision of transforming cancer treatment, and give back to their communities.

TransCode Therapeutics fosters an inclusive and diverse work environment where teammates can thrive and contribute to the company's mission of transforming cancer treatment. They value the unique perspectives and experiences of their employees, creating a culture where everyone feels respected, valued, and empowered.